drugset
drugset / Trial / NCT06014528

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

NCT06014528 ↗

Phase 2 Recruiting 168 enrolled InxMed (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).

Timeline

Start
2022-09-06
Primary completion
2026-12-24
Completion
2026-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Ifebemtinib Small molecule 100 mg Oral
Background Doxorubicin Other / unclassified 40 mg/m2 Intravenous

Indications

ovarian carcinoma